List of Qbrexza drug patents

Qbrexza is owned by Journey.

Qbrexza contains Glycopyrronium Tosylate.

Qbrexza has a total of 8 drug patents out of which 0 drug patents have expired.

Qbrexza was authorised for market use on 28 June, 2018.

Qbrexza is available in cloth;topical dosage forms.

Qbrexza can be used as topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

The generics of Qbrexza are possible to be released after 28 February, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10548875 JOURNEY Glycopyrrolate salts
Feb, 2033

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052267 JOURNEY Topical glycopyrrolate formulations
Oct, 2028

(5 years from now)

US8618160 JOURNEY Topical glycopyrrolate formulations
Dec, 2029

(6 years from now)

US9744105 JOURNEY Topical glycopyrrolate formulations
Jul, 2030

(7 years from now)

US10004717 JOURNEY Glycopyrrolate salts
Feb, 2033

(9 years from now)

US10543192 JOURNEY Glycopyrrolate salts
Feb, 2033

(9 years from now)

US8859610 JOURNEY Crystalline glycopyrrolate tosylate
Feb, 2033

(9 years from now)

US9259414 JOURNEY Glycopyrrolate salts
Feb, 2033

(9 years from now)

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Market Authorisation Date: 28 June, 2018

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

How can I launch a generic of QBREXZA before it's patent expiration?
More Information on Dosage

QBREXZA family patents

23

United States

5

European Union

4

Korea, Republic of

4

Australia

3

Mexico

2

Japan

2

Israel

2

Spain

2

Canada

1

Hong Kong

1

New Zealand

1

Singapore

1

China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic